• Tsung-Yu Tsai, Kun-Hua Tu, Feng-Chun Tsai, Yu-Yun Nan, Pei-Chun Fan, Chih-Hsiang Chang, Ya-Chung Tian, Ji-Tseng Fang, Chih-Wei Yang, and Yung-Chang Chen.
• College of Medicine, Chang Gung University, Taoyuan, Taiwan.
• BMC Anesthesiol. 2019 May 15; 19 (1): 73.

BackgroundExtracorporeal membrane oxygenation (ECMO) is often used in critical patients with severe myocardial failure. However, the mortality rate of patients on ECMO is often high. Recent studies have suggested that endothelial activation with subsequent vascular barrier breakdown is a critical pathogenic mechanism of organ damage and is related to the outcome of critical illness. This study aimed to determine whether endothelial biomarkers can be served as prognostic factors for the outcome of patients on ECMO.MethodsThis prospective study enrolled 23 critically ill patients on veno-arterial ECMO in the intensive care units of a tertiary care hospital between March 2014 and February 2015. Serum samples were tested for thrombomodulin, angiopoietin (Ang)-1, Ang-2, and vascular endothelial growth factor (VEGF). Demographic, clinical, and laboratory data were also collected.ResultsThe overall mortality rate was 56.5%. The combination of Ang-2 at the time of ECMO support (day 0) and VEGF at day 2 had the ability to discriminate mortality (area under receiver operating characteristic curve [AUROC], 0.854; 95% confidence interval: 0.645-0.965).ConclusionsIn this study, we found that the combination of Ang-2 at day 0 and VEGF at day 2 was a modest model for mortality discrimination in this group of patients.

27 keywords...

hide…